Cefixime is NOT appropriate for treating uncomplicated bacterial skin infections
Cefixime is not indicated for skin and soft tissue infections and should not be used for this purpose. The FDA-approved indications for cefixime are limited to uncomplicated urinary tract infections, otitis media, pharyngitis/tonsillitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea—skin infections are notably absent 1.
Why Cefixime is the Wrong Choice
The 2014 IDSA guidelines for skin and soft tissue infections do not include cefixime in their treatment recommendations 2. This is not an oversight—cefixime lacks adequate activity against the primary pathogens responsible for skin infections:
- Staphylococcus aureus (including MSSA): Cefixime has poor activity against staphylococci 3
- Streptococcus pyogenes: While cefixime has some streptococcal activity, it is not the preferred agent
The clinical literature confirms this gap: studies of cefixime focus exclusively on respiratory, urinary, and ENT infections—not skin infections 4, 5, 3.
What You Should Use Instead
For uncomplicated bacterial skin infections (cellulitis, simple abscesses after drainage), the IDSA guidelines recommend 2:
For MSSA or Streptococcal Infections:
- Cephalexin 500 mg four times daily (oral agent of choice)
- Dicloxacillin 500 mg four times daily
- Cefazolin 1 g every 8 hours IV (if parenteral therapy needed)
For MRSA Coverage (if risk factors present):
- Trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily
- Doxycycline 100 mg twice daily
- Clindamycin 300-450 mg four times daily
Pediatric Dosing (≥6 months):
- Cephalexin 25-50 mg/kg/day in 4 divided doses
- Clindamycin 30-40 mg/kg/day in 3 divided doses
Key Clinical Pitfalls
Do not confuse third-generation cephalosporins with first-generation agents. While cefixime is a third-generation oral cephalosporin with excellent gram-negative coverage, it sacrifices the gram-positive (especially staphylococcal) activity that makes first-generation cephalosporins like cephalexin ideal for skin infections 6.
Assess for MRSA risk factors before choosing empiric therapy: prior MRSA infection, injection drug use, recent hospitalization, or purulent drainage with systemic signs. These patients need MRSA-active agents, not cefixime 2.